

Role of FBP17 in the Podosome and Phagocytic Cup Formation




FIGURE 2. The importance of FBP17 in the formation of podosomes and phagocytic cups. *A*, expression of FBP17 was reduced by transfection of siRNA. THP-1 cells were transfected with siRNA for FBP17 (siFBP; lanes 2 and 4) or its scrambled control siRNA (siC; lanes 1 and 3). Lysates prepared from total transfected cells were analyzed by immunoblotting for FBP17 (lanes 1 and 2) and β -actin (lanes 3 and 4). *B* and *C*, effects of FBP17 siRNA on the formation of podosomes and phagocytic cups in macrophages. Human primary monocytes were co-transfected with siFBP (closed bars) or siC (open bars) and an FITC-conjugated control siRNA and then differentiated into macrophages with M-CSF-1. FITC-positive transfected cells were examined for the formation of podosomes (*B*) or phagocytic cups (*C*), and the percentage of cells with podosomes or phagocytic cups was scored. *D* and *E*, effects of FBP17 siRNA on the functions of podosomes and phagocytic cups. Macrophages co-transfected with siFBP (closed bars) or siC (open bars) and the FITC-conjugated control siRNA were assayed for macrophage migration (*D*) or phagocytosis of IgG-opsonized latex beads (*E*). Data represent the mean \pm S.D. of triplicate experiments. *F–I*, immunofluorescence micrographs of a representative cell from each experiment. Cells transfected with siC (*F*) and siFBP (*G*) were stained with Alexa Fluor 568-phalloidin. Cells transfected with siC (*H*) or siFBP (*I*) were incubated with IgG-opsonized latex beads and then stained with phalloidin. The left and right panels are phase contrast and immunofluorescence micrographs, respectively. The bar is 10 μ m.

THP-1 cells was estimated to be 40–50% from the expression of green fluorescent protein (GFP) used as a transfection control. Therefore, the decrease in FBP17 expression indicates that FBP17 was efficiently knocked down in most transfected cells.

Human primary monocytes were co-transfected with the FBP17 siRNAs and a FITC-conjugated control siRNA as a transfection marker. After differentiation of the monocytes into macrophages with M-CSF-1, FITC-positive cells were examined for the formation of podosomes and phagocytic cups. To quantify their formation, we scored the percentage of cells with podosomes or phagocytic cups among FITC-positive cells. When the expression of FBP17 was knocked down, the formation of both podosomes and phagocytic cups in macrophages was significantly reduced ($p < 0.01$; Fig. 2, *B* and *C*). These results suggest that FBP17 is necessary for the formation of podosomes and phagocytic cups. A representative cell from each experiment is shown in Fig. 2, *F* and *G*, for podosomes and in Fig. 2, *H* and *I*, for phagocytic cups. We then assayed macrophage migration as a podosome function and phagocytosis as a phagocytic cup function. When expression of FBP17 was knocked down, macrophage migration through a gelatin filter toward a chemoattractant was significantly reduced in cells transfected with FBP17 siRNA ($p < 0.02$; Fig. 2*D*). Phagocytosis of IgG-opsonized latex beads was also reduced (Fig. 2*E*). These results suggest that FBP17 is essential for chemotaxis and phagocytosis because of its role in forming podosomes and phagocytic cups, respectively.

FBP17 Recruits the WASP-WIP Complex to the Plasma Membrane—Recent biochemical analyses revealed that FBP17 binds to a membrane phospholipid, phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂), through its EFC/F-BAR domain and to N-WASP and dynamin via its SH3 domain (18, 21, 24). We have shown that although WASP and WIP are cytosolic proteins, the WASP-WIP complex localizes at podosomes and phagocytic cups (4, 16). We then examined whether FBP17 recruits the WASP-WIP complex to the plasma membrane in macrophages. We focused on the roles of the EFC and SH3 domains of FBP17 and constructed three FBP17 mutants for the recruitment experiments: a Lys-33 to Glu (K33E) substitution, a Lys-166 to Ala (K166A) substitution, and an SH3 domain deletion (dSH3). Both substitution mutations in the EFC domain (K33E and K166A) significantly reduce membrane binding and deformation (22), and the dSH3 mutant does not bind to WASP and WIP because the SH3 domain is the binding site of WASP and WIP (Fig. 1*F*). We co-transfected HEK293 cells with the FLAG-tagged FBP17 constructs, WASP, and WIP. A C-terminal fragment (1146–1429 amino acids) of PDZ-GDP exchange factor (PDZ-GEF) was used as a negative control for FBP17 because this fragment is stable in the cytosol and does not interact with any WASP-related proteins (4, 16, 25). We confirmed the expression of FBP17 and its mutants in cells by immunoblotting (supplemental Fig. 2) and immunoprecipitated FLAG-tagged proteins from lysates of the transfected cells with anti-FLAG antibody (Fig. 3*A*, lanes 1–5). WASP and WIP were detected in the immunoprecipitates from cells

Role of FBP17 in the Podosome and Phagocytic Cup Formation




FIGURE 3. FBP17 recruits WASP, WIP, and dynamin-2 to the plasma membrane. *A*, HEK293 cells were co-transfected with cDNAs of the indicated FLAG-tagged proteins, Myc-tagged WASP, and HA-tagged WIP. The FLAG-tagged proteins were immunoprecipitated (IP) from lysates of the transfected cells with an anti-FLAG antibody followed by immunoblotting (WB) using antibodies to FLAG (lanes 1–5), WASP (lanes 6–10), and WIP (lanes 11–15). *B–F*, transfected HEK293 cells expressing FLAG-tagged proteins, Myc-WASP, and HA-WIP were double-stained with an anti-FLAG antibody and anti-WASP antibody. *B–F*, cells expressing FLAG-PDZ-GEF (*B*), FLAG-FBP17 (*C*), the FLAG-tagged FBP17 mutant with the K33E missense mutation (*D*), K166A (*E*), and the SH3-deleted FBP17 mutant dSH3 (*F*). The bar is 10 μ m.

expressing the FLAG-tagged FBP17, K33E, and K166A constructs (Fig. 3*A*, lanes 7–9 and 12–14) but not the FLAG-tagged PDZ-GEF and dSH3 constructs (Fig. 3*A*, lanes 6, 10, 11, and 15), indicating that FBP17 and its mutants K33E and K166A form a complex with WASP and WIP but that dSH3 not.

Next, cells expressing the FLAG-tagged proteins, WASP, and WIP were examined under the immunofluorescence microscope for the localization of the FLAG-tagged proteins and WASP. WASP and WIP were localized in the cytosol in cells transfected with only the WASP cDNA and only the WIP cDNA, respectively, as well as in cells expressing both WASP and WIP (supplemental Fig. 3). In cells co-expressing FLAG-PDZ-GEF (control) with WASP and WIP, both FLAG-PDZ-GEF and WASP were cytosolic (Fig. 3*B*). In cells co-expressing FLAG-FBP17 with WASP and WIP, FLAG-FBP17 localized at the plasma membrane because its EFC domain binds to the plasma membrane (Fig. 3*C*, left panel). In those cells, WASP also localized at the plasma membrane (Fig. 3*C*, right panel), indicating that FBP17 shifted the localization of WASP from the cytosol to the plasma membrane (Fig. 3, *B* and *C*). To con-

firm that the WASP-WIP complex was recruited to the plasma membrane, cells co-expressing FLAG-FBP17 with WASP and HA-tagged WIP were stained with an anti-FLAG monoclonal antibody and an anti-WASP polyclonal antibody or an anti-HA rat monoclonal antibody. Double staining revealed that both WASP and WIP co-localized with FLAG-FBP17 at the plasma membrane (supplemental Fig. 4, *A* and *B*). To further confirm the localization of the FBP17 mutants, cells co-expressing the FLAG-tagged FBP mutants, WASP, and WIP were stained with anti-FLAG monoclonal antibody. The K33E and K166A mutants were cytosolic and the SH3-deleted FBP17 mutant localized at the plasma membrane (supplemental Fig. 4*C*).

To determine the roles of the EFC and SH3 domains of FBP17 in this recruitment, we examined the localization of the FBP17 mutants and WASP in cells co-expressing the FBP mutants with WASP and WIP. Membrane tubulation in cells transfected with an FBP17 cDNA is an indicator of the membrane binding and deformation activities of FBP17 (18, 22). We detected *in vivo* membrane tubulation in cells expressing FBP17 and dSH3 but not in cells expressing K33E and K166A (supplemental Fig. 5). In cells co-expressing either FBP17 mutant (K33E or K166A) with WASP and WIP, both K33E and K166A were cytosolic (Fig. 3, *D* and *E*, left panels), and WASP was also cytosolic (Fig. 3, *D* and *E*, right panels). These results indicate that K33E and K166A are unable to recruit WASP to the plasma membrane, consistent with the inability of K33E and K166A to bind and deform the plasma membrane (supplemental Fig. 5).

The SH3-deleted FBP17 mutant, dSH3, localized at the plasma membrane (Fig. 3*F*, left panel) because its EFC domain is intact. However, WASP was cytosolic in cells co-expressing dSH3 with WASP and WIP (Fig. 3*F*, right panel), consistent with the inability of the dSH3 mutant to bind to WASP and WIP (Fig. 3*A*, lanes 5, 10, and 15).

To quantify the recruitment, we scored the percentage of cells in which WASP and WIP were localized at the plasma membrane. Cells expressing the FBP17 mutants (K33E, K166A, or dSH3) exhibited significantly lower plasma membrane localization of WASP and WIP than cells expressing FBP17 ($p < 0.05$; supplemental Fig. 6, *A* and *B*). FBP17 also recruited dynamin-2 to the plasma membrane, and both EFC and SH3 domains are necessary for this recruitment (supplemental Fig. 6*C*), as reported previously (18, 21). To confirm the localization of FBP17 and its mutants in cells co-expressing FBP17 with WASP, WIP, and dynamin-2, the transfected cells were stained with anti-FLAG monoclonal antibody. The wild-type FBP17 and dSH3 localized at the plasma membrane and the FLAG-PDZ-GEF (control) and the FBP mutants (K33E and K166A) were cytosolic (supplemental Fig. 6*D*).

Subcellular Localization of FBP17, WASP, WIP, and Dynamin-2 in Macrophages—To determine whether WASP, WIP, and dynamin-2 are recruited to the plasma membrane in macrophages when podosomes and phagocytic cups are formed, we examined the subcellular localization of FBP17, WASP, WIP, and dynamin-2 in macrophages forming podosomes or phagocytic cups. The cytosolic and membrane fractions were prepared from macrophages and analyzed by immunoblotting. Caspase-3 is a cytosolic marker, and sodium

Role of FBP17 in the Podosome and Phagocytic Cup Formation

potassium ATPase is a plasma membrane marker (26). FBP17 was detected in the membrane fraction from macrophages forming podosomes (Fig. 4A, lane 9). WASP, WIP, and

dynamin-2 were also detected in the membrane fraction, although they are cytosolic proteins (Fig. 4A, lanes 12, 15, and 18). FBP17 was detected in the membrane fraction from macrophages forming phagocytic cups (Fig. 4B, lane 9). WASP, WIP, and dynamin-2 were also detected in the membrane fractions from macrophages forming phagocytic cups (Fig. 4B, lanes 12, 15, and 18). These results, taken together with Fig. 3, suggest that FBP17 recruits the WASP-WIP complex and dynamin-2 to the plasma membrane in macrophages and that both the EFC and the SH3 domains are necessary for this recruitment.

The Role of Each Domain of FBP17 in the Formation of Podosomes and Phagocytic Cups—To determine the roles of the EFC and SH3 domains in the formation of podosomes and phagocytic cups, we examined whether overexpression of the FBP17 mutants affects the formation of these structures. We transfected THP-1 cells with the FBP17 constructs and confirmed the expression of FBP17 or the FBP17 mutants in transfected THP-1 cells by immunoblotting (Fig. 5A). When THP-1 cells were differentiated to obtain macrophage phenotypes with PMA, podosome formation was significantly reduced in cells overexpressing the K33E, K166A, and dSH3 FBP17 mutants when compared with the FBP17 wild type ($p < 0.01$; Fig. 5B). Phagocytic cup formation was also reduced in cells overexpressing the FBP17 mutants (Fig. 5C). These results indicate that the EFC domain and SH3 domain are essential for the formation of podosomes and phagocytic cups in macrophages.

Defects in Macrophages from WAS Patients—Our results suggest that the complex formation of FBP17 with WASP, WIP, and dynamin-2 at the plasma membrane is a critical step in the formation of podosomes and phagocytic cups (Figs. 1G, 3, and 4). In macrophages from WASP-deficient WAS patients, the complex does not form properly due to a lack of WASP expression. We examined macrophages from WASP-deficient WAS patients for the formation of podosomes and phagocytic cups. Two genetically independent WAS patients (WAS1, 211delT; and WAS2, 41–45delG) (27, 28) were assayed for the formation of those structures. Podosomes were completely absent (Fig. 6, A–C), and phagocytic cup formation was severely impaired (Fig. 6, D–F) in macrophages from both WAS patients, although FBP17, WIP, and dynamin-2 were expressed at the same level in patients as in normal individuals (Fig. 6G). In fact, the formation of podosomes and phagocytic cups was impaired in macrophages when the expression of WASP was reduced by siRNA transfection (4, 16).

This is the first result showing that both podosome and phagocytic cup formations are defective in macrophages from WASP-deficient patients. These results are consistent with the previous observations (3, 12).




FIGURE 4. Subcellular localization of FBP17, WASP, WIP, and dynamin-2 in macrophages. A, macrophages forming podosomes. B, macrophages forming phagocytic cups. Total lysates (T), the cytosolic fraction (C), and the membrane fraction (M) prepared from macrophages forming podosomes (A) or phagocytic cups (B) were analyzed by immunoblotting for caspase-3 (lanes 1–3), sodium potassium ATPase (Na-K Aase; lanes 4–6), FBP17 (lanes 7–9), WASP (lanes 10–12), WIP (lanes 13–15), and dynamin-2 (lanes 16–18). Caspase-3 and sodium potassium ATPase (Na-K ATPase) are markers for the cytosol and plasma membrane, respectively.




FIGURE 5. The role of the EFC and SH3 domains of FBP17 in the formation of podosomes and phagocytic cups. A, expression of FLAG-tagged proteins in transfected THP-1 cells. Total lysates prepared from transfected THP-1 cells were analyzed by immunoblotting (WB) using an anti-FLAG antibody. All of the FLAG-tagged proteins, FLAG-PDZ-GEF (control, lane 1), FLAG-FBP17 (lane 2), and the FBP17 mutants, K33E, K166A, and dSH3 (lanes 3–5) were expressed in THP-1 cells at similar levels. B and C, THP-1 cells co-transfected with cDNAs for the FLAG-tagged proteins and pmaxGFP were differentiated with PMA and then assayed for the formation of podosomes (B) and phagocytic cups (C). The percentage of cells with podosomes or phagocytic cups among all GFP-positive cells was scored. Data represent the mean \pm S.D. of triplicate experiments.

Role of FBP17 in the Podosome and Phagocytic Cup Formation




FIGURE 6. Defective formation of podosomes and phagocytic cups in macrophages from WAS patients. A–F, macrophages from a normal control and two genetically independent WAS patients (WAS1 and WAS2) were examined for the formation of podosomes (A–C) and phagocytic cups (D–F). The patients, WAS1 and WAS2, have the deletion mutations 211delT and 41–45delG, respectively, in their genomic DNAs. The bars are 10 μ m. G, expression levels of WASP, WIP, FBP17, dynamin-2, and β -actin in WAS patients. Lysates prepared from macrophages from a normal control and two WAS patients (WAS1 and WAS2) were subjected to immunoblotting. WASP was not detected in the lysates from these WAS patients (lanes 2 and 3). Podosomes were completely absent (A–C) and phagocytic cup formation was severely impaired (D–F) in macrophages from both WAS patients, although FBP17, WIP, and dynamin-2 were expressed at the same level in patients as in normal individuals (G) (lanes 4–12).

These results give us a natural example that supports the importance of the complex formation of FBP17 with WASP, WIP, and dynamin-2 for the formation of podosomes and phagocytic cups.

DISCUSSION

Cell biological and structural analyses of the EFC domain of FBP17 have shown that the EFC domain binds to and deforms the plasma membrane (18, 22). It has previously been shown that the SH3 domain of FBP17 binds to N-WASP and dynamin in transfected cells (18, 21). However, physiologically important processes to which those activities of FBP17 contribute were unknown. Here, we have demonstrated that FBP17 recruits the WASP-WIP complex from the cytosol to the plasma membrane and that this recruitment is necessary for the formation of podosomes and phagocytic cups in macrophages. Our results suggest that FBP17 facilitates membrane deformation and actin polymerization induced by the WASP-WIP complex to occur simultaneously at the same membrane sites and that both are required for the formation of podosomes and phagocytic cups. This is supported by the observations that

regulated actin polymerization is an essential process for the formation of podosomes (3) and phagocytic cups (29). Thus, FBP17 mediates a common molecular step in the formation of podosomes and phagocytic cups.

Macrophages have the ability to form both podosomes and phagocytic cups (Fig. 1, A–D). When macrophages having podosomes are stimulated with IgG-opsonized latex beads, the podosomes immediately disappear, and the phagocytic cups are formed at the site that the IgG beads attach. This observation indicates that the transition of the membrane structures occurs from podosomes to phagocytic cups. Macrophages migrate to sites of inflammation where they phagocytose pathogenic microbes and damaged tissue compounds and mediate local effector functions. Once macrophages encounter those materials at the site of inflammation, they stop migrating and phagocytose those materials. The transition of the macrophage functions occur from migration to phagocytosis. Podosomes and phagocytic cups are the essential membrane structures for migration and phagocytosis, respectively. Thus, the transition of the membrane structures from podosomes to phagocytic cups is essential and significant for the transition of the macrophage functions. Recently, two reports suggest that macrophage migration and phagocytosis include a common molecular mechanism to regulate actin cytoskeleton (40, 41). In this study, we identified a critical common molecular step mediated by FBP17 for the formation of podosomes and phagocytic cups, which are essential for migration and phagocytosis, respectively. In the future, elucidation of the molecular mechanisms underlying the transition would be intriguing.

It has been reported that dynamin-2 is also required for the formation of podosomes in transformed cells and osteoclasts (30–32) and phagocytic cups in a mouse macrophage cell line (33, 34) and that the FBP17-dynamin complex regulates the plasma membrane invagination (35). Our results suggest that FBP17 recruits dynamin-2 to the same site as membrane deformation and that this recruitment is also necessary for the formation of these structures (Figs. 3–5 and supplemental Fig. 6C). The formation of podosomes and phagocytic cups involves the process of the membrane protrusion (Fig. 1, A–D). The membrane protrusion requires the delivery of new membrane material (2). Our results, taken together with the above observations, suggest that dynamin-2 recruited by FBP17 to the plasma membrane probably plays an essential role in the formation of podosomes and phagocytic cups by regulating the recruitment of vesicles to the plasma membrane as new membrane material in macrophages.

Recently, the EFC domain of FBP17 was shown to bind strongly to the PI(4,5)P₂ (18, 22). On the other hand, it has been shown that PI(4,5)P₂ localizes at the podosomes in osteoclasts (36) and phagocytic cups (37, 38). These observations suggest that PI(4,5)P₂ is synthesized upon stimulation at the plasma membrane and plays an important role in the recruitment of FBP17 to the plasma membrane. Presumably, the PI(4,5)P₂ binding activity of the EFC domain is necessary for the localization of FBP17, and therefore, of the WASP-WIP complex and dynamin-2, at the sites where podosomes and phagocytic cups will form.

Role of FBP17 in the Podosome and Phagocytic Cup Formation

We suggest that the complex formation of FBP17 with WASP, WIP, and dynamin-2 at the plasma membrane is critical for the formation of podosomes and phagocytic cups (Figs. 1G and 3–5). In macrophages from WASP-deficient WAS patients, defects in the complex formation of FBP17 with WASP, WIP, and dynamin-2 impair the formation of podosomes and phagocytic cups (WAS1: 211delT (27); WAS2: 41–45delG(28) in Fig. 6), thereby reducing chemotaxis and phagocytosis by macrophages, which in turn would decrease the ability of host defense. The severity of WAS-associated symptoms was estimated and expressed as a score of 1–5. A score of 1 was assigned to patients with only thrombocytopenia and small platelets, and a score of 2 was assigned to patients with additional findings of mild, transient eczema or minor infections. Those with treatment-resistant eczema and recurrent infections despite optimal treatment received a score of 3 (mild WAS) or 4 (severe WAS). Regardless of the original score, if any patients then had autoimmune disease or malignancy, the score was changed to 5. The patients, WAS1 and WAS2, receive scores of 5 and 4, respectively. Both patients have the recurrent infections. We suggest that defective formation of podosomes and phagocytic cups in their macrophages (Fig. 6, A–F) reduces chemotaxis and phagocytosis, which are the critical processes to protect the body against infection, resulting in the recurrent infections. In addition, defective phagocytosis reduces the clearance of self-antigens such as apoptotic cells. This may cause the autoimmune diseases seen in WAS patients. In fact, Cohen *et al.* (39) recently reported that reduced clearance of apoptotic cells resulted in development of autoimmunity. Our findings therefore provide a potential mechanism for the recurrent infections and autoimmune diseases seen in WAS patients.

Acknowledgments—We thank Drs. M. Fukuda, R. C. Liddington, S. Courtneidge, A. Strongin (Burnham Institute for Medical Research), S. Grinstein (Hospital for Sick Children, Ontario, Canada), J. Condeelis (Albert Einstein Medical College), and P. De Camilli (Yale University) for critical reading of the manuscript and helpful discussion.

REFERENCES

- Linder, S., and Aepfelbacher, M. (2003) *Trends Cell Biol.* **13**, 376–385
- Linder, S. (2007) *Trends Cell Biol.* **17**, 107–117
- Linder, S., Nelson, D., Weiss, M., and Aepfelbacher, M. (1999) *Proc. Natl. Acad. Sci. U. S. A.* **96**, 9648–9653
- Tsuboi, S. (2007) *J. Immunol.* **178**, 2987–2995
- Carman, C. V., Sage, P. T., Sciuto, T. E., Fuente, M. A. d. l., Geha, R. S., Ochs, H. D., Dvorak, H. F., Dvorak, A. M., and Springer, T. A. (2007) *Immunity* **26**, 784–797
- Underhill, D. M., and Ozinsky, A. (2002) *Annu. Rev. Immunol.* **20**, 825–852
- Leverrier, Y., and Ridley, A. J. (2001) *Curr. Biol.* **11**, 195–199
- Wiskott, A. (1937) *Monatsschr. Kinderheilkd.* **68**, 212–216
- Aldrich, R. A., Steinberg, A. G., and Campbell, D. C. (1954) *Pediatrics* **13**, 133–139
- Notarangelo, L. D., Miao, C. H., and Ochs, H. D. (2008) *Curr. Opin. Hematol.* **15**, 30–36
- Derry, J. M., Ochs, H. D., and Francke, U. (1994) *Cell* **78**, 635–644; Correction (1994) *Cell* **79**, 922
- Lorenzi, R., Brickell, P. M., Katz, D. R., Kinnon, C., and Thrasher, A. J. (2000) *Blood* **95**, 2943–2946
- Ramesh, N., Anton, I. M., Hartwig, J. H., and Geha, R. S. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 14671–14676
- Anton, I. M., de la Fuente, M. A., Sims, T. N., Freeman, S., Ramesh, N., Hartwig, J. H., Dustin, M. L., and Geha, R. S. (2002) *Immunity* **16**, 193–204
- Chou, H. C., Anton, I. M., Holt, M. R., Curcio, C., Lanzardo, S., Worth, A., Burns, S., Thrasher, A. J., Jones, G. E., and Calle, Y. (2006) *Curr. Biol.* **16**, 2337–2344
- Tsuboi, S., and Meerloo, J. (2007) *J. Biol. Chem.* **282**, 34194–34203
- Tsuboi, S., Nonoyama, S., and Ochs, H. D. (2006) *EMBO Rep.* **7**, 506–511
- Tsujita, K., Suetsugu, S., Sasaki, N., Furutani, M., Oikawa, T., and Takenawa, T. (2006) *J. Cell Biol.* **172**, 269–279
- Chan, D. C., Bedford, M. T., and Leder, P. (1996) *EMBO J.* **15**, 1045–1054
- Ho, H. Y., Rohatgi, R., Lebensohn, A. M., Le, M., Li, J., Gygi, S. P., and Kirschner, M. W. (2004) *Cell* **118**, 203–216
- Kamioka, Y., Fukuhara, S., Sawa, H., Nagashima, K., Masuda, M., Matsuda, M., and Mochizuki, N. (2004) *J. Biol. Chem.* **279**, 40091–40099
- Shimada, A., Niwa, H., Tsujita, K., Suetsugu, S., Nitta, K., Hanawa-Suetsugu, K., Akasaka, R., Nishino, Y., Toyama, M., Chen, L., Liu, Z. J., Wang, B. C., Yamamoto, M., Terada, T., Miyazawa, A., Tanaka, A., Sugano, S., Shirouzu, M., Nagayama, K., Takenawa, T., and Yokoyama, S. (2007) *Cell* **129**, 761–772
- Auwerx, J. (1991) *Experientia (Basel)* **47**, 22–31
- Kakimoto, T., Katoh, H., and Negishi, M. (2006) *J. Biol. Chem.* **281**, 29042–29053
- Rebhun, J. F., Castro, A. F., and Quilliam, L. A. (2000) *J. Biol. Chem.* **275**, 34901–34908
- Takayama, S., Krajewski, S., Krajewska, M., Kitada, S., Zapata, J. M., Kochel, K., Knee, D., Scudiero, D., Tudor, G., Miller, G. J., Miyashita, T., Yamada, M., and Reed, J. C. (1998) *Cancer Res.* **58**, 3116–3131
- Jin, Y., Mazza, C., Christie, J. R., Giliani, S., Fiorini, M., Mella, P., Gandelini, F., Stewart, D. M., Zhu, Q., Nelson, D. L., Notarangelo, L. D., and Ochs, H. D. (2004) *Blood* **104**, 4010–4019
- Imai, K., Morio, T., Zhu, Y., Jin, Y., Itoh, S., Kajiwara, M., Yata, J., Mizutani, S., Ochs, H. D., and Nonoyama, S. (2004) *Blood* **103**, 456–464
- May, R. C., Caron, E., Hall, A., and Machesky, L. M. (2000) *Nat. Cell Biol.* **2**, 246–248
- Ochoa, G. C., Slepnev, V. I., Neff, L., Ringstad, N., Takei, K., Daniell, L., Kim, W., Cao, H., McNiven, M., Baron, R., and De Camilli, P. (2000) *J. Cell Biol.* **150**, 377–389
- McNiven, M. A., Baldassarre, M., and Buccione, R. (2004) *Front. Biosci.* **9**, 1944–1953
- Bruzzaniti, A., Neff, L., Sanjay, A., Horne, W. C., De Camilli, P., and Baron, R. (2005) *Mol. Biol. Cell* **16**, 3301–3313
- Gold, E. S., Underhill, D. M., Morrisette, N. S., Guo, J., McNiven, M. A., and Aderem, A. (1999) *J. Exp. Med.* **190**, 1849–1856
- Tse, S. M., Furuya, W., Gold, E., Schreiber, A. D., Sandvig, K., Inman, R. D., and Grinstein, S. (2003) *J. Biol. Chem.* **278**, 3331–3338
- Itoh, T., Erdmann, K. S., Roux, A., Habermann, B., Werner, H., and De Camilli, P. (2005) *Dev. Cell* **9**, 791–804
- Chelliah, M. A. (2005) *J. Biol. Chem.* **280**, 32930–32943
- Botelho, R. J., Teruel, M., Dierckman, R., Anderson, R., Wells, A., York, J. D., Meyer, T., and Grinstein, S. (2000) *J. Cell Biol.* **151**, 1353–1368
- Dewitt, S., Tian, W., and Hallett, M. B. (2006) *J. Cell Sci.* **119**, 443–451
- Cohen, P. L., Caricchio, R., Abraham, V., Camenisch, T. D., Jennette, J. C., Roubey, R. A., Earp, H. S., Matsushima, G., and Reap, E. A. (2002) *J. Exp. Med.* **196**, 135–140
- Brandt, D. T., Marion, S., Griffiths, G., Watanabe, T., Kaibuchi, K., and Grosse, R. (2007) *J. Cell Biol.* **178**, 193–200
- Kato, M., Khan, S., d'Aniello, E., McDonald, K. J., and Hart, D. N. J. (2007) *J. Immunol.* **179**, 6052–6063
- Calle, Y., Anton, I. M., Thrasher, A. J., and Jones, G. E. (2008) *J. Microsc. (Oxf.)* **231**, 494–505

Angiopoietin-1 Induces Krüppel-like Factor 2 Expression through a Phosphoinositide 3-Kinase/AKT-dependent Activation of Myocyte Enhancer Factor 2^{*[S]}

Received for publication, September 8, 2008, and in revised form, November 24, 2008. Published, JBC Papers in Press, December 23, 2008, DOI 10.1074/jbc.M806928200

Keisuke Sako[‡], Shigetomo Fukuhara^{†1}, Takashi Minami[§], Takao Hamakubo[§], Haihua Song[§], Tatsuhiko Kodama[§], Akiyoshi Fukamizu[¶], J. Silvio Gutkind^{||}, Gou Young Koh^{**}, and Naoki Mochizuki[‡]

From the [‡]Department of Structural Analysis, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan, the [†]Laboratory for System Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, 4-6-1, Komaba, Meguro, Tokyo 153-8904, Japan, the [§]Center for Tsukuba Advanced Research Alliance, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan, the [¶]Oral and Pharyngeal Cancer Branch, NIDCR, National Institutes of Health, Bethesda, Maryland 20892, and the ^{**}Biomedical Research Center and Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Guseong-dong, Daejeon 305-701, Korea

Angiopoietin-1 (Ang1) regulates both vascular quiescence and angiogenesis through the receptor tyrosine kinase Tie2. We and another group have recently shown that Ang1 and Tie2 form distinct signaling complexes at cell-cell and cell-matrix contacts and further demonstrated that the former selectively induces expression of Krüppel-like factor 2 (KLF2), a transcription factor involved in vascular quiescence. Here, we investigated the mechanism of how Ang1/Tie2 signal induces KLF2 expression to clarify the role of KLF2 in Ang1/Tie2 signal-mediated vascular quiescence. Ang1 stimulated KLF2 promoter-driven reporter gene expression in endothelial cells, whereas it failed when a myocyte enhancer factor 2 (MEF2)-binding site of KLF2 promoter was mutated. Depletion of MEF2 by siRNAs abolished Ang1-induced KLF2 expression, indicating the requirement of MEF2 in KLF2 induction by Ang1. Constitutive active phosphoinositide 3-kinase (PI3K) and AKT increased the MEF2-dependent reporter gene expression by enhancing its transcriptional activity and stimulated the KLF2 promoter activity cooperatively with MEF2. Consistently, inhibition of either PI3K or AKT and depletion of AKT abrogated Ang1-induced KLF2 expression. In addition, we confirmed the dispensability of extracellular signal-regulated kinase 5 (ERK5) for Ang1-induced KLF2 expression. Furthermore, depletion of KLF2 resulted in the loss of the inhibitory effect of Ang1 on vascular endothelial growth factor (VEGF)-mediated expression

of vascular cell adhesion molecule-1 in endothelial cells and VEGF-mediated monocyte adhesion to endothelial cells. Collectively, these findings indicate that Ang1/Tie2 signal stimulates transcriptional activity of MEF2 through a PI3K/AKT pathway to induce KLF2 expression, which may counteract VEGF-mediated inflammatory responses.

Angiopoietin-1 (Ang1)² is a ligand for endothelium-specific receptor tyrosine kinase Tie-2. Gene-targeting analyses of either *Ang1* or *Tie2* in mice reveal an essential role of Ang1/Tie2 signaling in developmental vascular formation (1–3). In adult vasculature, Ang1/Tie2 signal maintains quiescence of mature blood vessels by enhancing vascular integrity and endothelial survival (4–6). However, Tie2 signaling is also involved in physiological and pathological angiogenesis, as opposed to the maintenance of vascular quiescence (4, 5, 7–9). As to this question, we and Alitalo's group (10, 11) have recently clarified that the distinct localization of Tie2 in the presence or absence of cell-cell contact determines the specificity of downstream signaling of Tie2. Ang1 induces *trans*-association of Tie2 at endothelial cell-cell contacts, whereas Tie2 is anchored to extracellular matrix by Ang1 in the absence of cell-cell contacts. *Trans*-associated Tie2 bridged by Ang1 and extracellular matrix-anchored Tie2 by Ang1 induce distinct signaling pathways preferable for vascular quiescence and angiogenesis via AKT and extracellular signal-regulated kinase (ERK) 1/2, respectively. By performing DNA microarray analysis, we also revealed that a distinct set of genes is regulated by Ang1 in the presence or absence of cell-cell contacts. Among them, Krüp-

* This work was supported by grants from the Ministry of Education, Science, Sports and Culture of Japan (to K. S., S. F., and N. M.); the Ministry of Health, Labour, and Welfare of Japan (to N. M.); and the Program for the Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (to S. F., T. M., T. K., and N. M.); the Naito Foundation (to S. F.); Takeda Science Foundation (to S. F.); the Sagawa Foundation for Promotion of Cancer Research (to S. F.); Mochida Memorial Foundation for Medical and Pharmaceutical Research (to S. F.); Kowa Life Science Foundation (to S. F.); Kanoe Foundation for the Promotion of Medical Science (to S. F.); and Takeda Medical Research Foundation (to N. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[†] This article was selected as a Paper of the Week.

[‡] The on-line version of this article (available at <http://www.jbc.org>) contains five supplemental figures.

¹ To whom correspondence should be addressed. Tel.: 81-6-6833-5012; Fax: 81-6-6835-5461; E-mail: fuku@ri.ncvc.go.jp.

² The abbreviations used are: Ang1, angiopoietin-1; KLF2, Krüppel-like factor 2; COMP, cartilage oligomeric matrix protein; MEF2, myocyte enhancer factor 2; ERK, extracellular signal-regulated kinase; PI3K, phosphoinositide 3-kinase; VEGF, vascular endothelial growth factor; VEGFR2, VEGF receptor 2; VCAM-1, vascular cell adhesion molecule-1; GFP, green fluorescent protein; GST, glutathione S-transferase; HUVEC, human umbilical vein endothelial cell; RT, reverse transcription; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HDAC, histone deacetylase; PCAF, p300/CBP-associated factor; CBP, CREB-binding protein; CREB, cAMP-response element-binding protein; BSA, bovine serum albumin; siRNA, small interfering RNA; MOPS, 4-morpholinepropanesulfonic acid; wt, wild type; mut, mutant; Luc, luciferase; CA, constitutive active.

pel-like factor 2 (KLF2) was selectively induced by Ang1 in the presence of cell-cell contacts (10).

KLF2 is a zinc finger family of transcription factor functioning in both vascular smooth muscle cells and endothelial cells and is, therefore, essential in developmental vascular formation (12–15). The *KLF2* knock-out mice exhibit impaired blood vessel formation attributable to the lack of smooth muscle cell recruitment (12). *KLF2* expression in endothelium is induced by laminar shear stress and is thought to act as a molecular transducer of laminar shear stress (16–18). In the adult human vasculature, *KLF2* expression is found at laminar segments of blood vessels and is decreased at branched points, which are more prone to develop atherosclerotic lesions (18), suggesting the role of *KLF2* as a flow-mediated atheroprotective factor. Consistently, more than 15% of flow-regulated genes are dependent upon flow-mediated *KLF2* induction (19).

It has been reported that laminar shear stress induces *KLF2* expression via an ERK5-myocyte enhancer factor 2 (MEF2) signaling pathway (19, 20). The MEF2 family of transcription factors is composed of four members (MEF2A, MEF2B, MEF2C, and MEF2D) and is known as a regulator of vascular functions (21–23). Therefore, *KLF2* may act downstream of MEF2 to regulate vascular functions.

KLF2 controls endothelial functions by negatively regulating inflammation and angiogenesis, thereby contributing to the maintenance of vascular quiescence (24–27). *KLF2* inhibits cytokine-mediated induction of pro-inflammatory targets such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin (24, 25). In addition to anti-inflammatory action, *KLF2* also down-regulates expression of vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2), leading to the inhibition of VEGF-induced angiogenesis and hyperpermeability (26, 27). Similarly, Ang1 functions as an anti-inflammatory and anti-permeability factor (6, 29). Ang1 inhibits VEGF-stimulated leukocyte adhesion to endothelium by reducing expression of cell adhesion molecules such as VCAM-1 and E-selectin (30). Furthermore, Ang1 counteracts VEGF-induced hyperpermeability *in vitro* and *in vivo* (29, 31–33). Our previous data that Ang1 induced *KLF2* expression (10) and the common roles by Ang1 and *KLF2* for vascular quiescence prompted us to test our hypothesis that Ang1/Tie2 signal may maintain the vascular quiescence through *KLF2* induction and to investigate how *KLF2* is induced by Ang1/Tie2 signaling.

In this study, we found that Ang1/Tie2 signal stimulates transcriptional activity of MEF2 through a phosphoinositide 3-kinase (PI3K)/AKT pathway to induce *KLF2* expression. Moreover, we revealed that Ang1-induced signaling functionally competes with VEGF-induced inflammatory responses.

EXPERIMENTAL PROCEDURES

Reagents, Antibodies, siRNAs, and Recombinant Protein—Ang1 and cartilage oligomeric matrix protein (COMP)-Ang1 were prepared as described before (34). VEGF was purchased from R&D Systems. Wortmannin and AKT inhibitor IV were obtained from Calbiochem. We generated anti-*KLF2* monoclonal antibody against amino acids 2–34 of human *KLF2*. Anti-green fluorescent protein (GFP) antibody was prepared as described before (35). Other antibodies were purchased as fol-

lows: anti-tubulin, anti-ERK5, anti-FLAG (M2), and anti- β -actin from Sigma-Aldrich; anti-MEF2 from Santa Cruz Biotechnology; anti-phospho-AKT, anti-AKT, anti-phospho-ERK1/2, and anti-ERK1/2 from Cell Signaling Technology; horseradish peroxidase-coupled sheep anti-mouse and anti-rabbit IgG from GE Healthcare Life Sciences; and Alexa Fluor 488-labeled secondary antibody from Molecular Probes. Stealth siRNAs targeting the genes indicated below were purchased from Invitrogen: human *KLF2* (HSS145585, HSS145587), human *ERK5* (HSS140815), human *AKT1* (validated stealth RNA interference: 12935-001), human *AKT2* (validated stealth RNA interference: 12937-40), human *MEF2A* (HSS106435, HSS106436), human *MEF2C* (HSS106438, HSS106439), and human *MEF2D* (HSS106441, HSS106442). Glutathione *S*-transferase (GST) fusion protein containing transactivating domain of MEF2C (GST-MEF2C) was prepared as described before (36).

Plasmids and Adenoviruses—A luciferase reporter plasmid containing the proximal 221-bp region of *KLF2* promoter (*KLF2*wt-Luc) was kindly provided by M. K. Jain (Case Western Reserve University). The MEF2-binding site of the *KLF2*wt-Luc plasmid was mutated using the QuikChange site-directed mutagenesis kit (Stratagene) using the *KLF2*wt-Luc vector as a template. Expression plasmids encoding MEF2C and constitutive active mutants of AKT (pCEFL-myrAKT) and PI3K- γ (pcDNA3-PI3K γ -CAAX) and a luciferase reporter plasmid containing a single MEF2-binding site (pGL3-MEF2) have already been described (36–38). A cDNA encoding full-length MEF2C amplified by PCR using pCEFL-GST-MEF2C as a template was inserted into p3xFLAG CMV10 vector (Sigma-Aldrich) or cloned into pCMV-DBD vector (Stratagene) to construct the plasmid expressing a Gal4 DNA-binding domain (DBD)-MEF2C fusion protein (Gal4/MEF2C). Plasmids encoding Gal4/MEF2C mutant proteins (Thr-293, Thr-300, Ser-387 (phosphorylation sites by ERK5 and p38), and Thr-404 (potential phosphorylation site by AKT) were replaced with Ala, and 6 Lys residues (Lys-116, Lys-119, Lys-234, Lys-239, Lys-252, Lys-264; acetylation sites by p300) replaced with Arg were generated using the QuikChange site-directed mutagenesis kit. An expression vector encoding FLAG-tagged HDAC5 was generously obtained from C. Grozinger (Harvard University). Other vectors are purchased as follows: pRL-SV40 and pRL-TK from Promega Corp.; pEGFP-C1 from Clontech; and pFR from Stratagene. Recombinant adenovirus vectors encoding GFP and constitutively active form of AKT were kindly provided by H. Kurose (Kyushu University) and Y. Fujio (Osaka University), respectively.

Cell Culture, Transfection, siRNA-mediated Protein Knock-down, and Adenovirus Infection—Human umbilical vein endothelial cells (HUVECs) were cultured as described previously (10) and used for experiments before passage 7. HUVECs were placed on collagen-coated plates at a density of 2,000 cells/cm² and 40,000 cells/cm² and cultured overnight to obtain sparse and confluent cell cultures, respectively. U937 cells, a human monocyte-like cell line, were cultured in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum, 50 units/ml penicillin, and 50 μ g/ml streptomycin. HUVECs were transfected using Lipofectamine 2000 reagent (Invitrogen) and Lipofectamine Plus reagent (Invitrogen) according to the manufac-

Ang1-induced KLF2 Expression via MEF2 Activation by PI3K/AKT




FIGURE 1. Ang1 induces KLF2 expression in confluent HUVECs. *A*, sparse (open bars) and confluent (closed bars) HUVECs were starved in medium 199 containing 1% BSA for 6 h and stimulated with COMP-Ang1 (C-Ang1) at the concentrations indicated at the bottom (ng/ml) for 1 h. After the stimulation, total RNA was extracted and subjected to real-time RT-PCR analysis to determine the expression level of KLF2 mRNA as described under "Experimental Procedures." Bar graphs show relative mRNA levels of KLF2 normalized to that of GAPDH. KLF2 mRNA levels are expressed relative to that in confluent cells stimulated with 400 ng/ml COMP-Ang1. Data are shown as means \pm S.D. of six independent experiments. *B*, confluent HUVECs starved for 6 h were stimulated with 400 ng/ml COMP-Ang1 for the periods indicated at the bottom (h) (COMP-Ang1 was used at the concentration of 400 ng/ml throughout the following experiments). KLF2 mRNA levels were analyzed by real-time RT-PCR as described in *A*. Values are expressed relative to that in the unstimulated cells and shown as means \pm S.D. of five independent experiments. *C*, confluent HUVECs were starved in HuMedia EB2 medium containing 0.5% fetal calf serum for 12 h and stimulated with COMP-Ang1 for the periods indicated at the top (h). Cell lysates were subjected to Western blot analysis with anti-KLF2 (top panel) and anti-tubulin (bottom panel) antibodies. *D*, confluent HUVECs were stimulated with vehicle (control), 600 ng/ml Ang1 (Ang1), and COMP-Ang1 (C-Ang1) for 1 h. KLF2 mRNA levels were determined as described in *A*. Values are expressed relative to that in the control cells and shown as means \pm S.D. of six independent experiments. Significant differences between two groups (*A*) or from the control (*B* and *D*) are indicated as **, $p < 0.01$ or ***, $p < 0.001$. n.s. indicates no significance between two groups.

turer's instructions. For siRNA-mediated gene silencing, HUVECs were transfected with siRNA duplexes using Lipofectamine RNAiMAX reagent (Invitrogen) and used for the experiments 48–72 h after transfection. HUVECs were infected with adenovirus vectors at the appropriate multiplicity of infection. Forty-eight h after infection, the cells were used for experiments.

Real-time Reverse Transcription-PCR—Sparse and confluent HUVECs plated on collagen-coated plates were starved in medium 199 containing 1% BSA for 6 h and stimulated with COMP-Ang1 as described in the figure legends. The cells were stimulated in the presence of 30 μ M wortmannin or 8 μ M AKT inhibitor IV. To examine the effect of COMP-Ang1 on VEGF-induced VCAM-1 expression, HUVECs starved in medium 199 containing 0.5% BSA for 5 h were prestimulated with or without COMP-Ang1 for 1 h and subsequently challenged with VEGF

for 3 h. After the stimulation, total RNA was purified using TRIzol (Invitrogen). Quantitative real-time reverse transcription (RT)-PCR was carried out using QuantiFast SYBR Green RT-PCR kit (Qiagen) as described before (10). For each reaction, 100 ng of total RNA was transcribed for 10 min at 50 $^{\circ}$ C followed by a denaturing step at 95 $^{\circ}$ C for 5 min and 40 cycles of 10 s at 95 $^{\circ}$ C and 30 s at 60 $^{\circ}$ C. Fluorescence data were collected and analyzed using Mastercycler ep realplex (Eppendorf). The primers used for amplification were as follows: for human KLF2, 5'-CTACACCAAGGTTCGCATCTG-3' and 5'-CCGTGTGCTTTCGGTAGTG-3'; for human VCAM1, 5'-CAAATCCTTGATACTGCTCATC-3' and 5'-TTGACTTCTTGCTCACAGC-3'; for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5'-ATGGGGAAGGTGAAGGTCG-3' and 5'-GGGGTCATTGATGGCAACAATA-3'. For normalization, expression of human GAPDH was determined in parallel as an endogenous control.

Detection of KLF2 Protein Expression—To examine the KLF2 protein expression induced by COMP-Ang1, confluent HUVECs plated on a collagen-coated dish were starved in Humedia-EB2 medium (Kurabo) containing 0.5% fetal calf serum for 12 h and stimulated with 400 ng/ml COMP-Ang1 for the periods as indicated in the figure legends. After the stimulation, the cells were washed once

with ice-cold phosphate-buffered saline, harvested by scraping, and pelleted by centrifugation at 4,000 \times g for 10 min at 4 $^{\circ}$ C. The cell pellets were then lysed at 4 $^{\circ}$ C in radioimmune precipitation buffer containing 50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 1 \times protease inhibitor mixture. The cell lysates were subjected to SDS-PAGE and Western blot analysis as described previously (39).

Detection of ERK5, AKT, and ERK1/2 Activities—Confluent and sparse HUVECs plated on collagen-coated dish were starved in medium 199 containing 1% BSA for 6 h and stimulated with 400 ng/ml COMP-Ang1 for 15 min. The cells were then lysed at 4 $^{\circ}$ C in lysis buffer containing 25 mM HEPES at pH 7.5, 0.3 M NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM dithiothreitol, 20 mM β -glycerophosphate, 1 mM sodium vanadate, 1% Triton X-100, and 1 \times protease inhibitor mixture. To meas-

Ang1-induced KLF2 Expression via MEF2 Activation by PI3K/AKT




FIGURE 2. MEF2 is responsible for Ang1-induced KLF2 expression. *A*, structures of KLF2wt-Luc and KLF2mut-Luc reporter constructs are shown. *B*, confluent HUVECs were transfected with either KLF2wt-Luc (left) or KLF2mut-Luc (right) reporter construct together with pRL-SV40 vector. After transfection, the cells were stimulated without (–) or with (+) COMP-Ang1 (C-Ang1) in 1% BSA-containing medium 199 for 24 h. The medium was replaced with the freshly prepared same medium every 6 h. After the stimulation, the cells were collected, and the lysates were assayed for firefly and *Renilla* luciferase activities as described under “Experimental Procedures.” The data represent firefly luciferase activity normalized by the *Renilla* luciferase activity present in each cellular lysate. Values are expressed as a percentage relative to that observed in the KLF2wt-Luc transfected cells treated with vehicle and shown as mean \pm S.D. of three independent experiments. *C*, confluent HUVECs transfected with control siRNA (control) or with two independent MEF2 siRNA mixtures (MEF2#1 and MEF2#2; each mixture contains siRNAs targeting MEF2A, MEF2C, and MEF2D) were stimulated as described in the legend for Fig. 1 (panel D). KLF2 mRNA levels were determined as described in the legend for Fig. 1 (panel A). Values are expressed relative to that in the control siRNA-transfected cells treated with vehicle and shown as means \pm S.D. of three independent experiments. *D*, confluent HUVECs transfected with control siRNA or with MEF2 siRNA mixture (MEF2#1) were starved and stimulated with vehicle (–) or COMP-Ang1 (+) as described in the legend for Fig. 1 (panel C). Cell lysates were subjected to Western blot analysis with anti-KLF2 (top panel), anti-MEF2 (middle panel), and anti-tubulin (bottom panel) antibodies. In *B* and *C*, significant differences between two groups are indicated as **, $p < 0.01$, or ***, $p < 0.001$. *n.s.* indicates no significance between two groups.

ure the ERK5 activity, *in vitro* kinase assay was performed as described previously (40). Briefly, endogenous ERK5 was immunoprecipitated from aliquots of cell lysate with anti-ERK5 antibody at 4 °C for 3 h, and the immunocomplexes were recovered with protein G-Sepharose beads (GE Healthcare Life Sciences). Beads were washed three times with phosphate-buffered saline containing 1% Nonidet P-40 and 2 mM sodium vanadate, once with washing buffer containing 100 mM Tris at pH 7.5 and 0.5 M LiCl and once with kinase reaction buffer containing 12.5 mM MOPS at pH 7.5, 12.5 mM β -glycerophosphate, 7.5 mM MgCl₂, 0.5 mM EGTA, 0.5 mM sodium vanadate, and 0.5 mM sodium fluoride. Samples were then resuspended in 15 μ l of kinase reaction buffer containing 3 μ g of GST-MEF2C, 1 μ Ci of [γ -³²P]ATP, and 20 μ M cold ATP and incubated at 37 °C for 90 min. ³²P-labeled substrates were separated by SDS-PAGE and detected by autoradiography. To evaluate the phosphorylation of AKT and ERK1/2, aliquots of cell lysate were subjected to Western blot analysis with anti-phospho-AKT and




FIGURE 3. Ang1-induced KLF2 expression does not require ERK5. *A*, sparse (left) and confluent (right) HUVECs were starved in medium 199 containing 1% BSA for 6 h and stimulated with vehicle (–) or COMP-Ang1 (C-Ang1) (+) for 15 min. To measure the ERK5 activity, *in vitro* kinase assay was performed using anti-ERK5 immunoprecipitates from the corresponding cell lysates as described under “Experimental Procedures.” ³²P-labeled substrates are shown at the top (MEF2C (kinase)). In parallel, cell lysates were subjected to Western blot analysis with anti-ERK5 (ERK5), anti-phosphoAKT (pAKT), anti-AKT (AKT), anti-phosphoERK1/2 (pERK1/2), and anti-ERK1/2 (ERK1/2) antibodies. *B*, confluent HUVECs transfected with control siRNA (left) or ERK5 siRNA (right) were starved and stimulated with vehicle (–) or COMP-Ang1 (+) as described in the legend for Fig. 1 (panel D). KLF2 mRNA levels were determined and expressed as described in the legend for Fig. 2 (panel C). Values are shown as means \pm S.D. of five independent experiments. Significant differences between two groups are indicated as ***, $p < 0.001$. *C*, confluent HUVECs transfected with control or ERK5 siRNA were starved and stimulated as described in the legend for Fig. 1 (panel C). Cell lysates were subjected to Western blot analysis with anti-KLF2 (top panel), anti-ERK5 (middle panel), and anti-tubulin (bottom panel) antibodies.

anti-phospho-ERK1/2 antibodies, respectively. The total contents of ERK5, AKT, and ERK1/2 in each cell lysate were also assayed in a parallel run using corresponding antibodies.

Luciferase Reporter Assay—Luciferase reporter assay was carried out as described before (36, 40). Confluent HUVECs plated on a collagen-coated 12-well plate were transfected with different expression vectors, together with reporter plasmids as described in the figure legends. The total amount of plasmid DNA was adjusted with empty vector. To examine the effect of COMP-Ang1, the cells were starved and stimulated as described in the figure legends. The cells were lysed using passive lysis buffer (Promega), and luciferase activities in cell extract were determined using a Dual-Luciferase assay system (Promega).

Detection of Subcellular Localization of FLAG-tagged HDAC5—Confluent HUVECs plated on a collagen-coated glass base dish were transfected with the plasmid encoding FLAG-tagged histone deacetylase (HDAC) 5. Twenty-four h after the transfection, the cells were starved in medium 199 containing 0.5% BSA for 6 h and subsequently stimulated with vehicle, COMP-Ang1, or VEGF for 3 h. After the stimulation, the cells were fixed and stained with anti-FLAG antibody as

Ang1-induced KLF2 Expression via MEF2 Activation by PI3K/AKT




FIGURE 4. Ang1 does not induce nuclear export of HDAC5. *A*, confluent HUVECs plated on a collagen-coated glass base dish were transfected with the plasmid encoding FLAG-tagged HDAC5. After 24 h, the cells were starved in medium 199 containing 0.5% BSA for 6 h and stimulated with vehicle (*control*: upper panel), COMP-Ang1 (*C-Ang1*: middle panel), or 50 ng/ml VEGF (*bottom panel*) for 3 h. After the stimulation, the cells were fixed, immunostained with anti-FLAG antibody, and visualized with Alexa Fluor 488-conjugated secondary antibody. Alexa Fluor 488 and phase contrast images are shown at the left and right columns, respectively. *B*, nuclear export of HDAC5 by vehicle (*control*), COMP-Ang1 (*C-Ang1*), and VEGF observed in *A* was quantified. The number of cells expressing FLAG-tagged HDAC5 in the cytoplasm was counted and expressed as a percentage relative to the total number of cells expressing FLAG-tagged HDAC5. At least 100 cells were scored for each treatment. Values are expressed as means \pm S.D. of three independent experiments. Significant difference from the control is indicated as ***, $p < 0.001$. *n.s.* indicates no significant difference from the control.

described before (10). Protein reacting with antibody was visualized with Alexa Fluor 488-conjugated secondary antibody. Alexa Fluor 488 and phase contrast images were recorded with an Olympus IX-81 inverted fluorescence microscope. The number of cells expressing FLAG-tagged HDAC5 in the cytoplasm among FLAG-tagged HDAC5-expressing cells was counted. Nuclear export of HDAC5 was determined by the HDAC5 in the cytoplasm instead of the nucleus. At least 100 cells were scored for each experiment.

Monocyte Adhesion Assay—HUVECs transfected with control or KLF2 siRNA were placed on collagen-coated 24-well plates at the density of 40,000 cells/cm², cultured overnight, and starved in medium 199 containing 1% BSA for 2 h. The cells were prestimulated with 400 ng/ml COMP-Ang1 for 1 h and challenged with vehicle or 50 ng/ml VEGF in the presence or absence of COMP-Ang1 for 4 h. U937 cells labeled with green fluorescent dye PKH67 (Sigma-Aldrich) were added to the confluent HUVEC monolayers (8×10^5 cells/well) and incubated in RPMI 1640 containing 1% fetal bovine serum for 90 min. The cells were then washed three times with prewarmed Hank's buffered salt solution (Invitrogen) and fixed with 2% formaldehyde. Phase contrast and PKH67 fluorescent images were recorded with an Olympus IX-81 inverted fluorescence microscope. The adherent U937 cells were quantified by measuring fluorescent intensity at five randomly selected fields in each well using MetaMorph 6.1 software (Molecular Devices Corp.).

Statistical Analysis—The values are expressed as means \pm S.D. Statistical significance was determined using one-way

analysis of variance, two-way analysis of variance, or unpaired *t* test. *p* values < 0.05 were considered statistically significant.

RESULTS

Ang1 Induces KLF2 Expression in Confluent but Not Sparse Cultures of HUVECs—To first examine the KLF2 expression downstream of *trans*-associated Tie2 at cell-cell contacts and cell-substratum contact-anchored Tie2 in response to Ang1, HUVECs were stimulated with COMP-Ang1, a potent Ang1 variant, under either confluent or sparse culture condition. COMP-Ang1 concentration-dependently induced KLF2 mRNA expression in confluent HUVECs but not in the sparse cells (Fig. 1*A*). Consistently, KLF2 protein expression was up-regulated upon stimulation with COMP-Ang1 (Fig. 1*C*). KLF2 mRNA and protein expression by COMP-Ang1 peaked at 1 h after the stimulation and then declined to the basal level by 6 h (Fig. 1, *B* and *C*). KLF2 mRNA level was increased in

response to native Ang1 as well as COMP-Ang1 (Fig. 1*D*). Taken together with the previously reported evidence that Ang1 induces *trans*-association of Tie2 in the presence of cell-cell contacts (10, 11), these results suggest that *trans*-associated Tie2 at cell-cell contacts is capable of inducing KLF2 expression.

Ang1 Induces KLF2 Expression through MEF2—Next, we sought to delineate the signaling pathway responsible for Ang1-induced KLF2 expression. It has been reported that laminar shear stress and statins activate the KLF2 promoter via a single MEF2-binding site located at $-120/-111$ bp upstream from the transcriptional initiation site (19, 41, 42). Thus, we investigated the role of MEF2 in Ang1-induced KLF2 expression. HUVECs were transfected with either luciferase reporter plasmid in which the reporter is driven by the proximal 221-bp region (-221 bp upstream from the initiation site) of KLF2 promoter (KLF2wt-Luc) or by its MEF2-binding site-mutated promoter (KLF2mut-Luc) (Fig. 2*A*). COMP-Ang1 significantly induced KLF2 promoter-regulated reporter activity, whereas it failed to induce reporter activation when KLF2 promoter lacked MEF2-binding site (Fig. 2*B*), suggesting the indispensable role of MEF2 in Ang1-induced KLF2 expression. To further confirm the requirement of MEF2 for Ang1-induced KLF2 expression, we employed an siRNA technique to down-regulate MEF2 family proteins including MEF2A, MEF2C, and MEF2D. Depletion of these MEF2 proteins inhibited COMP-Ang1-induced both KLF2 mRNA expression and KLF2 protein expression (Fig. 2, *C* and *D* and supplemental Fig. S1). These findings

Ang1-induced KLF2 Expression via MEF2 Activation by PI3K/AKT

indicate that KLF2 expression induced by Ang1 depends upon MEF2.

Ang1-induced KLF2 Expression Is Not Mediated by the Signaling Pathways Involving ERK5 and HDAC5—ERK5 stimulates transcriptional activity of MEF2 factors by phosphorylating their transactivating domains (36, 43, 44). Previous reports indicate that KLF2 expression is severely impaired in ERK5-null mouse embryo (45) and that laminar shear stress stimulates ERK5 activity to induce MEF2-dependent KLF2 expression (19). Therefore, we examined whether Ang1 stimulates ERK5 activity under either confluent or sparse conditions to investigate the involvement of ERK5 in KLF2 induction by Ang1. COMP-Ang1 preferentially activated ERK5 as well as ERK1/2 in sparse HUVECs (Fig. 3A). However, stimulation of confluent cells with COMP-Ang1 did not enhance ERK5 kinase activity, although AKT was potentially activated under this condition (Fig. 3A). These results suggest that Ang1 induces KLF2 expression independently of ERK5. Consistently, depletion of ERK5 by siRNAs did not affect COMP-Ang1-induced KLF2 mRNA and protein expression (Fig. 3, B and C).

Class II HDACs, consisting of HDAC4, HDAC5, HDAC7, and HDAC9, interact with MEF2 and repress the expression of MEF2 target genes (46). Phosphorylation of class II HDACs by calcium/calmodulin-dependent protein kinase and protein kinase D results in their nuclear exclusion, leading to the enhancement of MEF2 transcriptional activity (46–48). Therefore, we examined whether Ang1 induces nuclear export of class II HDACs to enhance MEF2 activity. COMP-Ang1 did not induce nuclear export of FLAG-tagged HDAC5, although VEGF did (Fig. 4), suggesting that Ang1-induced KLF2 expression does not depend upon the inhibition of class II HDACs.

A PI3K/AKT Pathway Is Responsible for Ang1-induced KLF2 Expression—Ang1 is able to induce KLF2 expression only under confluent condition as described above (Fig. 1A). Under this condition, an AKT pathway is preferentially activated by Ang1 (Fig. 3A). These evidences prompted us to investigate whether the AKT pathway is responsible for KLF2 induction by Ang1. COMP-Ang1-induced KLF2 expression was completely blocked by wortmannin and AKT inhibitor IV, inhibitors for PI3K and AKT, respectively (Fig. 5, A and B). Furthermore, we examined the involvement of AKT in Ang1-mediated KLF2 expression by depleting AKT using siRNAs for AKT. Depletion of AKT prevented both COMP-Ang1-induced KLF2 mRNA expression and COMP-Ang1-induced KLF2 protein expression (Fig. 5, C and D). These results indicate that a PI3K/AKT pathway is indispensable for Ang1-induced KLF2 expression.

A PI3K/AKT Pathway Stimulates Transcriptional Activity of MEF2—To clarify whether a PI3K/AKT pathway stimulates MEF2-dependent transcription, HUVECs were transfected with a plasmid expressing luciferase reporter gene under the control of a single MEF2 site (MEF2-Luc) together with the plasmid encoding constitutive active AKT (AKT-CA) or PI3K (PI3K-CA). The reporter gene activity was only slightly stimulated by AKT-CA or PI3K-CA (Fig. 6A). However, coexpression of MEF2C significantly enhanced AKT-CA- or PI3K-CA-induced reporter gene expression (Fig. 6A). To further investigate whether MEF2-dependent transcription stimulated by




FIGURE 5. A PI3K/AKT pathway is involved in Ang1-induced KLF2 expression. *A*, confluent HUVECs starved for 6 h were pretreated with vehicle (*control*) or 30 nM wortmannin (*wort.*) for 30 min and subsequently stimulated with vehicle (–) or COMP-Ang1 (C-Ang1) (+) for 1 h. KLF2 mRNA levels were determined as described in the legend for Fig. 1 (*panel A*). Values are expressed relative to that in the wortmannin-untreated cells stimulated with vehicle and shown as means \pm S.D. of five independent experiments. *B*, confluent HUVECs starved for 6 h were pretreated with vehicle (*control*) or 8 μ M AKT inhibitor for 10 min and subsequently stimulated with vehicle (–) or COMP-Ang1 (+) for 1 h. KLF2 mRNA levels were determined and expressed as described in *A*. Data are shown as means \pm S.D. of four independent experiments. *C*, confluent HUVECs transfected with control siRNA (*control*) or with two independent AKT siRNA mixtures (*AKT#1* and *AKT#2*; each mixture contains siRNAs targeting AKT1 and AKT2) were starved and stimulated as described in the legend for Fig. 1 (*panel D*). KLF2 mRNA levels were determined and expressed as described in the legend for Fig. 2 (*panel C*). Values are shown as means \pm S.D. of four independent experiments. *D*, confluent HUVECs transfected with control siRNA or with two independent AKT siRNA mixtures (*AKT#1* and *AKT#2*) were starved and stimulated as described in the legend for Fig. 1 (*panel C*). Cell lysates were subjected to Western blot analysis with anti-KLF2 (*top panel*), anti-AKT (*middle panel*), and anti-tubulin (*bottom panel*) antibodies. In *A–C*, significant differences between two groups are indicated as ***, $p < 0.001$.

PI3K-CA and AKT-CA is ascribed to the enhanced transcriptional activity, we fused full-length MEF2C with DNA-binding domain of yeast Gal4 protein (Gal4/MEF2C) and tested the direct effect of AKT and PI3K on transcriptional activity of Gal4/MEF2C. AKT-CA and PI3K-CA potently stimulated the transcriptional activity of Gal4/MEF2C but not that of Gal4 (Fig. 6B). In addition, stimulation with COMP-Ang1 evoked Gal4/MEF2C-dependent reporter gene expression (Fig. 6C). Collectively, these findings indicate that Ang1/Tie2 signal stimulates the transcriptional activity of MEF2 through a PI3K/AKT pathway.

A PI3K/AKT/MEF2 Signaling Axis Stimulates the KLF2 Promoter—We further investigated the functional role of a PI3K/AKT/MEF2 pathway in Ang1-induced KLF2 expression. When HUVECs were transfected with the KLF2wt-Luc reporter gene along with the plasmid encoding GFP, AKT-CA, or PI3K-CA, AKT-CA and PI3K-CA induced more luciferase expression than GFP (Fig. 6D). The stimulatory effects of

Ang1-induced KLF2 Expression via MEF2 Activation by PI3K/AKT




FIGURE 6. A PI3K/AKT pathway stimulates transcriptional activity of MEF2, leading to KLF2 expression. *A*, confluent HUVECs were cotransfected with pGL3-MEF2 and pRL-TK vectors, together with the plasmid encoding either GFP or MEF2C as indicated at the bottom. The expression vector for GFP, AKT-CA, or PI3K-CA was also included in the transfection mixture as shown at the left. The cells were lysed 24 h after the transfection. Luciferase activities were assayed and presented as described in the legend for Fig. 2 (panel B). Data are expressed as a percentage relative to that observed in the cells expressing both PI3K-CA and MEF2C and shown as mean \pm S.D. of four independent experiments. *B*, confluent HUVECs were cotransfected with pFR and pRL-TK vectors, along with the plasmid expressing either Gal4 (left) or Gal4-MEF2C (right) as indicated at the bottom. The expression vector for GFP, AKT-CA, or PI3K-CA was also included in the transfection mixture as shown at the left. After 24 h of incubation, luciferase activities were assayed and represented as described in the legend for Fig. 2 (panel B). Data are expressed as a percentage relative to that observed in the cells expressing both Gal4-MEF2C and PI3K-CA and shown as mean \pm S.D. of three independent experiments. *C*, confluent HUVECs transfected with the plasmid encoding Gal4-MEF2C together with pGal4-Luc and pRL-SV40 reporter plasmids were starved and stimulated as described in the legend for Fig. 2 (panel B). Luciferase activities were assayed and presented as described in the legend for Fig. 2 (panel B). Data are expressed as a percentage relative to that observed in the control cells and shown as mean \pm S.D. of four independent experiments. *D*, confluent HUVECs were cotransfected with pRL-TK vector, along with either KLF2wt-Luc or KLF2mut-Luc reporter gene, and also with the expression vector for either GFP or MEF2C as indicated at the bottom. The plasmid encoding GFP, AKT-CA, or PI3K-CA was also included in the transfection mixture as shown at the left. Twenty-four h after the transfection, luciferase activities were assayed and presented as described in the legend for Fig. 2 (panel B). Data are expressed as a percentage relative to that in the cells transfected with KLF2wt-Luc along with the vector encoding GFP and shown as mean \pm S.D. of four independent experiments. *E*, confluent HUVECs were infected without (–) or with adenoviruses encoding either GFP or AKT-CA as indicated at the top. Forty-eight h after infection, the cells were collected, and the lysates were subjected to Western blot analysis with anti-KLF2 (KLF2), anti-phosphoAKT (pAKT), anti-AKT (AKT), anti-GFP (GFP), and anti- β -actin (β actin) antibodies. Significant differences between two groups (*A*, *B*, and *D*) or from the control (*C*) are indicated as *, $p < 0.05$, **, $p < 0.01$, or ***, $p < 0.001$.

AKT-CA and PI3K-CA on the reporter gene activity were significantly augmented by coexpression of MEF2C (Fig. 6D). AKT-CA and PI3K-CA did not stimulate the luciferase expres-

sion driven by the mutant promoter that lacks the MEF2-binding site (the KLF2mut-Luc), even in the presence of MEF2C (Fig. 6D). In addition, adenovirus-mediated overexpression of AKT-CA potentially induced both mRNA and protein expression of KLF2 in HUVECs (Fig. 6E and supplemental Fig. S2). Collectively, these results suggest that Ang1/Tie2 signal induces KLF2 expression through a PI3K/AKT/MEF2 signaling axis.

How does a PI3K/AKT signaling enhance transcriptional activity of MEF2? MEF2 activity is known to be regulated by its posttranslational modification such as phosphorylation and acetylation (49). We examined the effect of a PI3K/AKT pathway on posttranslational modification of MEF2C. We constructed the plasmids encoding Gal4/MEF2C mutants: 1) Gal4/MEF2C-ERK5/p38mut in which potential phosphorylation sites of MEF2C by p38 and ERK5 mitogen-activated protein (MAP) kinases (Thr-293, Thr-300, and Ser-387 corresponding to those in human MEF2C) were replaced by Ala (43, 50) and 2) Gal4/MEF2C-AKT mutant in which consensus phosphorylation site of MEF2C by AKT (Thr-404 corresponding that in human MEF2C) was mutated to Ala; and 3) Gal4/MEF2C-6KR in which the 6 Lys residues in MEF2C acetylated by p300 (Lys-116, Lys-119, Lys-234, Lys-239, Lys-252, and Lys-264 corresponding to those in human MEF2C) were replaced by Arg (51). Using these plasmids, MEF2-dependent transcription was directly tested in the cells expressing PI3K-CA. Expression of PI3K-CA could stimulate transcriptional activity mediated by mutant MEF2C to a similar extent to wild type MEF2C (supplemental Fig. S3). These results suggest that the posttranslational modification by ERK5, p38, AKT, and p300 is not required for PI3K/AKT pathway-stimulated MEF2 transcriptional activity.

Ang1 Inhibits VEGF-induced Inflammatory Responses through KLF2—We finally addressed the significance of Ang1/Tie2-dependent KLF2 expression in the cells. KLF2 has potent

Ang1-induced KLF2 Expression via MEF2 Activation by PI3K/AKT




FIGURE 7. KLF2 is responsible for the inhibitory effect of Ang1 on VEGF-induced inflammation. *A*, confluent HUVECs transfected with control or KLF2 siRNA were starved and stimulated as described in the legend for Fig. 1 (*panel C*). Cell lysates were subjected to Western blot analysis with anti-KLF2 (*top panel*) and anti-tubulin (*bottom panel*) antibodies. *B*, confluent HUVECs transfected with control or KLF2 siRNA were starved in medium 199 containing 0.5% BSA for 6 h. The cells prestimulated with or without COMP-Ang1 (C-Ang1) for 1 h were challenged with vehicle (–) or 50 ng/ml VEGF (+) for 3 h. VCAM-1 mRNA levels were analyzed by real-time RT-PCR as described in the legend for Fig. 1 (*panel A*). Values are expressed as a percentage relative to that observed in the cells transfected with control siRNA and stimulated with VEGF in the absence of COMP-Ang1. Data are shown as means \pm S.D. of three independent experiments. *C*, confluent HUVECs transfected with control or KLF2 siRNA were starved in medium 199 containing 1% BSA for 2 h. The cells prestimulated with (+) or without (–) COMP-Ang1 for 1 h were challenged with vehicle (*control*) or 50 ng/ml VEGF (*VEGF*) for 4 h. PKH67 fluorescent dye-labeled U937 cells were adhered to the HUVEC monolayers for 90 min. After fixation, phase contrast and PKH67 fluorescent (*green*) images were recorded with an Olympus IX-81 inverted fluorescence microscope. Shown are representative merged images. *D*, adhesion of U937 cells to HUVECs observed in *C* was quantified as described under “Experimental Procedures.” Values are expressed as a percentage relative to that observed in the cells transfected with control siRNA and stimulated with VEGF in the absence of COMP-Ang1. Data are shown as means \pm S.D. of four independent experiments. Significant differences between two groups are indicated as ***, $p < 0.001$. *n.s.* indicates no significance between two groups.

anti-inflammatory effects on the vascular endothelium (19, 24, 25). Ang1 also has anti-inflammatory effects and is known to counteract VEGF-induced inflammation (29, 30). Therefore, we hypothesized that Ang1 may inhibit VEGF-induced inflammation by inducing KLF2. To address this question, by depleting KLF2 using siRNA, we examined the effect of Ang1 through KLF2 on VEGF-induced VCAM-1 expression and VEGF-mediated monocyte adhesion to HUVECs. COMP-Ang1 partly inhibited VEGF-induced VCAM-1 expression and VEGF-induced adhesion of U937 cells to HUVECs (Fig. 7 and supplemental Figs. S4 and S5). However, these inhibitory effects of COMP-Ang1 were blunted by depletion of KLF2 (Fig. 7 and supplemental Figs. S4 and S5). These findings suggest that Ang1 competes with VEGF on inflammation through induction of KLF2.

DISCUSSION

Ang1/Tie2 signal is involved in both angiogenesis and vascular quiescence in adult vasculature. Recently, we and another

group have shown that endothelial cell-cell contacts specify downstream signaling pathways from Tie2 (10, 11). In the presence of cell-cell contacts, Ang1 induces *trans*-association of Tie2, leading to a preferential activation of the AKT pathway. In addition, we also found that KLF2 is specifically induced by *trans*-associated Tie2. Because KLF2 is a transcription factor involved in vascular quiescence, we hypothesized that KLF2 is responsible for Ang1/Tie2 signal-mediated vascular quiescence. To address this possibility, we tried to delineate the signaling pathways involved in Ang1-induced KLF2 expression. We found that Ang1/Tie2 signal stimulates transcriptional activity of MEF2 through a PI3K/AKT pathway, which in turn induces KLF2 expression.

MEF2 plays important roles not only in muscle development but also in regulation of blood vessels (21–23). MEF2C has been implicated as a regulator of endothelial integrity and permeability (21). Interestingly, MEF2C-deficient mice exhibit a similar defect in vascular development to KLF2-null mice (52). Our present data demonstrated that MEF2 is indispensable for Ang1-induced KLF2 expression. Therefore, defect of vascular development in Ang1-deficient mice might be partly due to the lack of MEF2-dependent KLF2 induction.

Several posttranslational modifications of MEF2 in the regulation of MEF2-mediated transcription has been reported (49). Among them, ERK5 regulates MEF2 transcriptional activity by phosphorylating its transcription activation domain (36, 43, 44). Parmar *et al.* (19) have reported that flow-mediated increase in KLF2 expression occurs via an ERK5/MEF2 pathway. Because ERK5 is essential for maintaining blood vessel integrity and is known to be stimulated by Ang1 (21, 22, 53), we examined whether ERK5 acts downstream of Ang1/Tie2 to induce KLF2 expression. Unexpectedly, Ang1 only stimulated the ERK5 activity in the absence of cell-cell contacts, and under this condition, KLF2 induction by Ang1 did not occur. Furthermore, knockdown of ERK5 did not prevent Ang1-induced KLF2 expression. Therefore, ERK5 appears to be dispensable for Ang1-induced KLF2 expression.

Our data show that Ang1/Tie2 signal utilizes a PI3K/AKT pathway instead of ERK5 to induce MEF2-dependent KLF2 expression. Similarly, it has been reported that a PI3K/AKT/

Ang1-induced KLF2 Expression via MEF2 Activation by PI3K/AKT

MEF2 pathway is used for insulin-like growth factor-induced myogenin expression (54). Huddleson *et al.* (42) have also shown that induction of KLF2 by shear stress requires a PI3K/chromatin-remodeling pathway. In contrast to our result, they claimed that AKT is not involved in this pathway, although it is activated by shear stress. We propose the involvement of AKT in Ang1-mediated KLF2 induction because 1) AKT inhibitor and knockdown of AKT both inhibit KLF2 mRNA and protein expression by COMP-Ang1; 2) AKT-CA induces the MEF2-dependent transcription and stimulates the KLF2 promoter cooperatively with MEF2; and 3) overexpression of AKT-CA induces both mRNA and protein expression of KLF2 in HUVECs. Currently, the reason for this discrepancy remains unclear, but it may be due to the different cell types used for the experiments. We performed the experiments with HUVECs, whereas they used an EOMA cell line. Alternatively, different stimuli such as Ang1 and shear stress may trigger distinct signaling pathways downstream of PI3K to stimulate KLF2 induction.

At present, a molecular link between AKT and MEF2 is still unknown. Recently, it has been reported that AKT directly phosphorylates transcriptional coactivator p300, leading to the association of MyoD with p300 and p300/CBP-associated factor (PCAF) (55). In addition, it has been also shown that p300 can physically interact with MEF2 as well as MyoD and enhances their transcriptional activity (28). Importantly, shear stress is shown to induce recruitment of p300 and PCAF into the KLF2 promoter (42). Therefore, the Ang1/Tie2/PI3K/AKT pathway may induce the association of MEF2 with transcriptional coactivators such as p300 and PCAF, thereby stimulating its transcriptional activity. p300 directly acetylates and stimulates MEF2 activity (51). However, PI3K-mediated activation of MEF2 is not mediated by such direct acetylation mechanism because transcriptional activity of acetylation-defective mutant of MEF2 could be stimulated by constitutive active PI3K (supplemental Fig. S3). Thus, further examination is required for clarifying the molecular link between AKT and MEF2.

KLF2 inhibits VEGF-induced angiogenesis and inflammation, possibly by maintaining vascular quiescence. Similarly, Ang1 counteracts VEGF-mediated inflammatory responses. Our present data suggest that inhibition of VEGF-mediated inflammatory responses by Ang1 depends upon KLF2. However, Ang1 also acts cooperatively with VEGF to induce angiogenesis in a certain situation (5, 7, 9). This opposite effect of Ang1 on VEGF-mediated responses may depend upon whether KLF2 is induced or not. In the presence of cell-cell contacts, Ang1/Tie2 signal is able to induce KLF2 expression and thereby inhibits VEGF-induced inflammation and angiogenesis. However, in the absence of cell-cell contacts, Ang1/Tie2 signal accelerates angiogenic signal because KLF2 is not induced in this condition, which accounts for the cooperation of Ang1 with VEGF. Therefore, KLF2 may be a key downstream factor from *trans*-associated Tie2 to maintain vascular quiescence.

In conclusion, we found that Ang1/Tie2 signal stimulates transcriptional activity of MEF2 through a PI3K/AKT pathway to induce KLF2 expression, thereby contributing to vascular quiescence.

Acknowledgments—We are grateful to M. K. Jain and G. B. Atkins (Case Western Reserve University) for the KLF2-Luc reporter plasmid, to Y. Fujio (Osaka University) for the adenovirus encoding AKT-CA, to C. Grozinger for the expression vector for HDAC5 (Harvard University), to K. Matsuo, M. Sone, M. Minamimoto, M. Maeoka, and Y. Matsuura for technical assistance, and to N. Takakura (Osaka University), M. Murakami (Kyoto University), H. Fujita (Osaka City University), and H. Daitoku (University of Tsukuba) for helpful advice.

REFERENCES

1. Dumont, D. J., Gradwohl, G., Fong, G. H., Puri, M. C., Gertsenstein, M., Auerbach, A., and Breitman, M. L. (1994) *Genes Dev.* **8**, 1897–1909
2. Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., and Yancopoulos, G. D. (1996) *Cell* **87**, 1171–1180
3. Sato, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., and Qin, Y. (1995) *Nature* **376**, 70–74
4. Wong, A. L., Haroon, Z. A., Werner, S., Dewhirst, M. W., Greenberg, C. S., and Peters, K. G. (1997) *Circ. Res.* **81**, 567–574
5. Peters, K. G., Kontos, C. D., Lin, P. C., Wong, A. L., Rao, P., Huang, L., Dewhirst, M. W., and Sankar, S. (2004) *Recent Prog. Horm. Res.* **59**, 51–71
6. Brindle, N. P., Saharinen, P., and Alitalo, K. (2006) *Circ. Res.* **98**, 1014–1023
7. Asahara, T., Chen, D., Takahashi, T., Fujikawa, K., Kearney, M., Magner, M., Yancopoulos, G. D., and Isner, J. M. (1998) *Circ. Res.* **83**, 233–240
8. Lin, P., Polverini, P., Dewhirst, M., Shan, S., Rao, P. S., and Peters, K. (1997) *J. Clin. Investig.* **100**, 2072–2078
9. Eklund, L., and Olsen, B. R. (2006) *Exp. Cell Res.* **312**, 630–641
10. Fukuhara, S., Sako, K., Minami, T., Noda, K., Kim, H. Z., Kodama, T., Shibuya, M., Takakura, N., Koh, G. Y., and Mochizuki, N. (2008) *Nat. Cell Biol.* **10**, 513–526
11. Saharinen, P., Eklund, L., Miettinen, J., Wirkkala, R., Anisimov, A., Wind-erlich, M., Nottebaum, A., Vestweber, D., Deutsch, U., Koh, G. Y., Olsen, B. R., and Alitalo, K. (2008) *Nat. Cell Biol.* **10**, 527–537
12. Kuo, C. T., Veselits, M. L., Barton, K. P., Lu, M. M., Clendenin, C., and Leiden, J. M. (1997) *Genes Dev.* **11**, 2996–3006
13. Lee, J. S., Yu, Q., Shin, J. T., Sebzda, E., Bertozzi, C., Chen, M., Mericko, P., Stadtfeld, M., Zhou, D., Cheng, L., Graf, T., MacRae, C. A., Lepore, J. J., Lo, C. W., and Kahn, M. L. (2006) *Dev. Cell* **11**, 845–857
14. Wu, J., Bohanan, C. S., Neumann, J. C., and Lingrel, J. B. (2008) *J. Biol. Chem.* **283**, 3942–3950
15. Atkins, G. B., and Jain, M. K. (2007) *Circ. Res.* **100**, 1686–1695
16. Dekker, R. J., van Soest, S., Fontijn, R. D., Salamanca, S., de Groot, P. G., VanBavel, E., Pannekoek, H., and Horrevoets, A. J. G. (2002) *Blood* **100**, 1689–1698
17. Huddleson, J. P., Srinivasan, S., Ahmad, N., and Lingrel, J. B. (2004) *Biol. Chem.* **385**, 723–729
18. Dekker, R. J., van Thienen, J. V., Rohlena, J., de Jager, S. C., Elderkamp, Y. W., Seppen, J., de Vries, C. J. M., Biessen, E. A. L., van Berkel, T. J. C., Pannekoek, H., and Horrevoets, A. J. G. (2005) *Am. J. Pathol.* **167**, 609–618
19. Parmar, K. M., Larman, H. B., Dai, G., Zhang, Y., Wang, E. T., Moorthy, S. N., Kratz, J. R., Lin, Z., Jain, M. K., Gimbrone, M. A., Jr., and Garcia-Cardena, G. (2006) *J. Clin. Investig.* **116**, 49–58
20. Kumar, A., Lin, Z., SenBanerjee, S., and Jain, M. K. (2005) *Mol. Cell. Biol.* **25**, 5893–5903
21. Hayashi, M., Kim, S. W., Imanaka-Yoshida, K., Yoshida, T., Abel, E. D., Eliceiri, B., Yang, Y., Ulevitch, R. J., and Lee, J. D. (2004) *J. Clin. Investig.* **113**, 1138–1148
22. Olson, E. N. (2004) *J. Clin. Investig.* **113**, 1110–1112
23. Wang, L., Fan, C., Topol, S. E., Topol, E. J., and Wang, Q. (2003) *Science* **302**, 1578–1581
24. SenBanerjee, S., Lin, Z., Atkins, G. B., Greif, D. M., Rao, R. M., Kumar, A., Feinberg, M. W., Chen, Z., Simon, D. I., Lusinskas, F. W., Michel, T. M., Gimbrone, M. A., Jr., Garcia-Cardena, G., and Jain, M. K. (2004) *J. Exp.*

Ang1-induced KLF2 Expression via MEF2 Activation by PI3K/AKT

- Med.* **199**, 1305–1315
25. Lin, Z., Hamik, A., Jain, R., Kumar, A., and Jain, M. K. (2006) *Arterioscler. Thromb. Vasc. Biol.* **26**, 1185–1189
26. Bhattacharya, R., SenBanerjee, S., Lin, Z., Mir, S., Hamik, A., Wang, P., Mukherjee, P., Mukhopadhyay, D., and Jain, M. K. (2005) *J. Biol. Chem.* **280**, 28848–28851
27. Dekker, R. J., Boon, R. A., Rondaij, M. G., Kragt, A., Volger, O. L., Elderkamp, Y. W., Meijers, J. C. M., Voorberg, J., Pannekoek, H., and Horrevoets, A. J. G. (2006) *Blood* **107**, 4354–4363
28. Sartorelli, V., Huang, J., Hamamori, Y., and Kedes, L. (1997) *Mol. Cell. Biol.* **17**, 1010–1026
29. Gamble, J. R., Drew, J., Trezise, L., Underwood, A., Parsons, M., Kasminkas, L., Rudge, J., Yancopoulos, G., and Vadas, M. A. (2000) *Circ. Res.* **87**, 603–607
30. Kim, I., Moon, S. O., Hoon Kim, S., Jin Kim, H., Soon Koh, Y., and Young Koh, G. (2001) *J. Biol. Chem.* **276**, 7614–7620
31. Gavard, J., Patel, V., and Gutkind, J. S. (2008) *Dev. Cell* **14**, 25–36
32. Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., and McDonald, D. M. (1999) *Science* **286**, 2511–2514
33. Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N., Holash, J., McDonald, D. M., and Yancopoulos, G. D. (2000) *Nat. Med.* **6**, 460–463
34. Cho, C. H., Kammerer, R. A., Lee, H. J., Steinmetz, M. O., Ryu, Y. S., Lee, S. H., Yasunaga, K., Kim, K. T., Kim, I., Choi, H. H., Kim, W., Kim, S. H., Park, S. K., Lee, G. M., and Koh, G. Y. (2004) *Proc. Natl. Acad. Sci. U. S. A.* **101**, 5547–5552
35. Sakurai, A., Fukuhara, S., Yamagishi, A., Sako, K., Kamioka, Y., Masuda, M., Nakaoka, Y., and Mochizuki, N. (2006) *Mol. Biol. Cell* **17**, 966–976
36. Marinissen, M. J., Chiariello, M., Pallante, M., and Gutkind, J. S. (1999) *Mol. Cell. Biol.* **19**, 4289–4301
37. Coso, O. A., Montaner, S., Fromm, C., Lacal, J. C., Prywes, R., Teramoto, H., and Gutkind, J. S. (1997) *J. Biol. Chem.* **272**, 20691–20697
38. Murga, C., Fukuhara, S., and Gutkind, J. S. (2000) *J. Biol. Chem.* **275**, 12069–12073
39. Fukuhara, S., Sakurai, A., Sano, H., Yamagishi, A., Somekawa, S., Takakura, N., Saito, Y., Kangawa, K., and Mochizuki, N. (2005) *Mol. Cell. Biol.* **25**, 136–146
40. Fukuhara, S., Marinissen, M. J., Chiariello, M., and Gutkind, J. S. (2000) *J. Biol. Chem.* **275**, 21730–21736
41. Sen-Banerjee, S., Mir, S., Lin, Z., Hamik, A., Atkins, G. B., Das, H., Banerjee, P., Kumar, A., and Jain, M. K. (2005) *Circulation* **112**, 720–726
42. Huddleson, J. P., Ahmad, N., Srinivasan, S., and Lingrel, J. B. (2005) *J. Biol. Chem.* **280**, 23371–23379
43. Kato, Y., Kravchenko, V. V., Tapping, R. I., Han, J., Ulevitch, R. J., and Lee, J. D. (1997) *EMBO J.* **16**, 7054–7066
44. Kato, Y., Zhao, M., Morikawa, A., Sugiyama, T., Chakravorty, D., Koide, N., Yoshida, T., Tapping, R. I., Yang, Y., Yokochi, T., and Lee, J. D. (2000) *J. Biol. Chem.* **275**, 18534–18540
45. Sohn, S. J., Li, D., Lee, L. K., and Winoto, A. (2005) *Mol. Cell. Biol.* **25**, 8553–8566
46. McKinsey, T. A., Zhang, C. L., and Olson, E. N. (2002) *Curr. Opin. Cell Biol.* **14**, 763–772
47. McKinsey, T. A., Zhang, C. L., Lu, J., and Olson, E. N. (2000) *Nature* **408**, 106–111
48. Vega, R. B., Harrison, B. C., Meadows, E., Roberts, C. R., Papst, P. J., Olson, E. N., and McKinsey, T. A. (2004) *Mol. Cell. Biol.* **24**, 8374–8385
49. Potthoff, M. J., and Olson, E. N. (2007) *Development (Camb.)* **134**, 4131–4140
50. Han, J., Jiang, Y., Li, Z., Kravchenko, V. V., and Ulevitch, R. J. (1997) *Nature* **386**, 296–299
51. Ma, K., Chan, J. K. L., Zhu, G., and Wu, Z. (2005) *Mol. Cell. Biol.* **25**, 3575–3582
52. Bi, W., Drake, C. J., and Schwarz, J. J. (1999) *Dev. Biol.* **211**, 255–267
53. Deng, Y., Yang, J., McCarty, M., and Su, B. (2007) *Am. J. Physiol.* **293**, C1404–C1411
54. Xu, Q., and Wu, Z. (2000) *J. Biol. Chem.* **275**, 36750–36757
55. Serra, C., Palacios, D., Mozzetta, C., Forcales, S. V., Morante, I., Ripani, M., Jones, D. R., Du, K., Jhala, U. S., Simone, C., and Puri, P. L. (2007) *Mol. Cell* **28**, 200–213

